Welcome, colleagues
New arrivals boost Institute's scientific and clinical
expertise
by Paul Hennessy
They are experts in genes that govern the life and death of cells, the genetic defects that lead to cancer, the development of new therapies, and management of top-level research operations. The eight senior and 12 junior faculty members who have joined Dana-Farber over the past four years represent the single biggest recruitment in the Institute's history, and one of the largest recruitments to any affiliate of Harvard Medical School.
More impressive than their numbers, though, is their scientific talent and potential for advancing the fields of cancer research and treatment. The Institute's new investigators were chosen not only because they are working in areas that promise to be exceptionally fruitful in the years ahead, but also because they bring a collegial spirit to a field where collaborative work is essential to progress. "The talent and expertise of this new generation is concrete evidence of the Institute's growing national leadership in cancer research," said Dana-Farber President David G. Nathan, M.D.
"The talent and expertise of this new generation is concrete evidence of the Institute's growing national leadership in cancer research."
— David G. Nathan, M.D. President, DFCI
The newcomers' interest in Dana-Farber is easy to understand. "For young or established researchers, there's something very appealing about working in a cancer center affiliated with one of America's great universities, that has a long, deep history of scientific advancement, and that has the heart, the resources, and the trustee support for the long march to success," says David Livingston, M.D., who chairs the Institute's Executive Committee for Research.
The benefits accrue to the Institute as well. The new scientists enrich and enliven the Institute's climate of scientific inquiry and broaden its base of expertise. "They increase our visibility as an institution of research and as a hospital," Livingston says. "Their presence gives us a more powerful voice, nationally and internationally, in the decisions that will influence the direction of cancer research in the years ahead."
Here is a brief look at some of the Institute's cadre of newly recruited senior faculty (listed alphabetically) and their areas of research interest. Their 12 junior faculty colleagues, who have also arrived recently at the Institute, are named at the end of this article.
- Next: Faye C. Austin, Ph.D., Director for Research
- Page: 1 | 2 | 3
